Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study
Objectives Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce. Methods In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral th...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
W.B. Saunders Ltd
2018
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| Sumario: | Objectives Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce. Methods In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART). Results A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5–74.1) of MDR-TB patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was demonstrated in only 23%. Conclusions Our results show that internationally recommended MDR-TB treatment regimens were infrequently used and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient population and the environment in which health care is provided. Urgent improvement of management of patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of TB/HIV care. © 2017 The British Infection Association |
|---|---|
| Bibliografía: | World Health Organization, Global Tuberculosis Report (2015), http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf, Available from: (Accessed 1 October 2017); Zumla, A., Chakaya, J., Centis, R., D'Ambrosio, L., Mwaba, P., Bates, M., Tuberculosis treatment and management–an update on treatment regimens, trials, new drugs, and adjunct therapies (2015) Lancet Respir Med, 3 (3), pp. 220-234 Daley, C.L., Caminero, J.A., Management of multidrug resistant tuberculosis (2013) Semin Respir Crit Care Med, 34 (1), pp. 44-59 Casali, N., Nikolayevskyy, V., Balabanova, Y., Harris, S.R., Ignatyeva, O., Kontsevaya, I., Evolution and transmission of drug-resistant tuberculosis in a Russian population (2014) Nat Genet, 46 (3), pp. 279-286 Acosta, C.D., Dadu, A., Ramsay, A., Dara, M., Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward (2014) Public Health Action, 4, pp. S3-12 Balabanova, Y., Ignatyeva, O., Fiebig, L., Riekstina, V., Danilovits, M., Jaama, K., Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference? (2016) Thorax, 71, pp. 854-861 Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., Hoffner, S., Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors (2013) Bull World Health Organ, 91 (1), pp. 36-45 Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., van Gemert, W., Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk (2012) Eur Respir J, 39 (6), pp. 1425-1431 UNAIDS, AIDS by the numbers (2015), http://www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf, WORLD AIDS DAY; Available from: (Accessed 1 October 2017); Yablonskii, P.K., Vizel, A.A., Galkin, V.B., Shulgina, M.V., Tuberculosis in Russia. Its history and its status today (2015) Am J Respir Crit Care Med, 191 (4), pp. 372-376 DeHovitz, J., Uuskula, A., El-Bassel, N., The HIV epidemic in Eastern Europe and Central Asia (2014) Curr HIV/AIDS Rep, 11 (2), pp. 168-176 Efsen, A.M., Schultze, A., Post, F.A., Panteleev, A., Furrer, H., Miller, R.F., Major challenges in clinical management of TB/HIV coinfected patients in Eastern Europe compared with Western Europe and Latin America (2015) PLoS ONE, 10 (12). , e0145380 Mocroft, A., Lundgren, J., Antinori, A., Monforte, A., Brannstrom, J., Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013 (2015) Euro Surveill, 20 (47) Post, F.A., Grint, D., Werlinrud, A.M., Panteleev, A., Riekstina, V., Malashenkov, E.A., Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe (2014) J Infect, 68 (3), pp. 259-263 Podlekareva, D.N., Efsen, A.M., Schultze, A., Post, F.A., Skrahina, A.M., Panteleev, A., Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study (2016) Lancet HIV, 3 (3), pp. e120-31 World Health Organization, Guidelines for the programmatic management of drug-resistant tuberculosis (2011), http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf, update; Available from: (Accessed 1 October 2017); Gunther, G., Gomez, G.B., Lange, C., Rupert, S., van Leth, F., Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey (2015) Eur Respir J, 45 (4), pp. 1081-1088 Lange, C., Abubakar, I., Alffenaar, J.W., Bothamley, G., Caminero, J.A., Carvalho, A.C., Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement (2014) Eur Respir J, 44 (1), pp. 23-63 World Health Organization, WHO treatment guidelines for drug-resistant tuberculosis (2016), http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf, update; Available from: (Accessed 1 October 2017); Conradie, F., Diacon, A., Everitt, D., Mendel, C., Niekerk, C., Howell, P., The NIX-TB Trial Of Pretomanid, Bedaquiline And Linezolid To TreaT XDR-TB (2017), Abstract number 80LB. Oral presentation from Conference on Retroviruses and Opportunistic Infections (CROI); Ahuja, S.D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J.N., Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients (2012) PLoS Med, 9 (8), p. e1001300 Abubakar, I., Zignol, M., Falzon, D., Raviglione, M., Ditiu, L., Masham, S., Drug-resistant tuberculosis: time for visionary political leadership (2013) Lancet Infect Dis, 13 (6), pp. 529-539 Strobe Group, Strobe statement (2009), http://strobe-statement.org/index.php?id=strobe-home, Available from: (Accessed 1 October 2017); World Health Organization, Treatment of tuberculosis guidelines fourth edition (2010), http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1, Available from: (Accessed 1 October 2017); Xie, Y.L., Chakravorty, S., Armstrong, D.T., Hall, S.L., Via, L.E., Song, T., Evaluation of a rapid molecular drug-susceptibility test for tuberculosis (2017) N Engl J Med, 377 (11), pp. 1043-1054 Zignol, M., Dean, A.S., Alikhanova, N., Andres, S., Cabibbe, A.M., Cirillo, D.M., Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project (2016) Lancet Infect Dis, 16 (10), pp. 1185-1192 Gunther, G., van Leth, F., Altet, N., Dedicoat, M., Duarte, R., Gualano, G., Beyond multidrug-resistant tuberculosis in Europe: a TBNET study (2015) Int J Tuberc Lung Dis, 19 (12), pp. 1524-1527 Podlekareva, D.N.S.A., Panteleev, A., Skrahina, A.M., Miro, J.M., Rakhmanova, A., Furrer, H., One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America (2016), and the; TB:HIV study in EuroCoord#; Accepted for publication in AIDS; Ahmad Khan, F., Gelmanova, I.Y., Franke, M.F., Atwood, S., Zemlyanaya, N.A., Unakova, I.A., Aggressive regimens reduce risk of recurrence after successful treatment of MDR-TB (2016) Clin Infect Dis, 63, pp. 214-220 Franke, M.F., Appleton, S.C., Mitnick, C.D., Furin, J.J., Bayona, J., Chalco, K., Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence (2013) Clin Infect Dis, 56 (6), pp. 770-776 Velasquez, G.E., Becerra, M.C., Gelmanova, I.Y., Pasechnikov, A.D., Yedilbayev, A., Shin, S.S., Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death (2014) Clin Infect Dis, 59 (1), pp. 9-15 Mansfeld, M., Skrahina, A., Shepherd, L., Schultze, A., Panteleev, A.M., Miller, R.F., Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe (2015) HIV Med, 16 (9), pp. 544-552 Abdool Karim, S.S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A., Timing of initiation of antiretroviral drugs during tuberculosis therapy (2010) N Engl J Med, 362 (8), pp. 697-706 Blanc, F.X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis (2011) N Engl J Med, 365 (16), pp. 1471-1481 Group, I.S.S., Lundgren, J.D., Babiker, A.G., Gordin, F., Emery, S., Grund, B., Initiation of antiretroviral therapy in early asymptomatic HIV infection (2015) N Engl J Med, 373 (9), pp. 795-807 Havlir, D.V., Kendall, M.A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S.S., Timing of antiretroviral therapy for HIV-1 infection and tuberculosis (2011) N Engl J Med, 365 (16), pp. 1482-1491 UNAIDS, 90-90-90 An ambitious treatment target to help end the AIDS epidemic (2014), http://www.unaids.org/en/resources/documents/2017/90-90-90, Available from: (Accessed 1 October 2017); Satti, H., McLaughlin, M.M., Hedt-Gauthier, B., Atwood, S.S., Omotayo, D.B., Ntlamelle, L., Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho (2012) PLoS ONE, 7 (10). , e46943 Shin, S.S., Modongo, C., Boyd, R., Caiphus, C., Kuate, L., Kgwaadira, B., High treatment success rates among HIV-infected multidrug-resistant tuberculosis patients after expansion of antiretroviral therapy in Botswana, 2006–2013 (2017) J Acquir Immune Defic Syndr, 74, pp. 65-71 Umanah, T., Ncayiyana, J., Padanilam, X., Nyasulu, P.S., Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa (2015) BMC Infect Dis, 15, p. 478 Isaakidis, P., Casas, E.C., Das, M., Tseretopoulou, X., Ntzani, E.E., Ford, N., Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis (2015) Int J Tuberc Lung Dis, 19 (8), pp. 969-978 Podlekareva, D.N., Panteleev, A.M., Grint, D., Post, F.A., Miro, J.M., Bruyand, M., Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe (2014) Eur Respir J, 43 (1), pp. 166-177 Morozova, O., Dvoryak, S., Altice, F.L., Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine (2013) Int J Drug Policy, 24 (6), pp. e91-8 |
| ISSN: | 01634453 |
| DOI: | 10.1016/j.jinf.2017.10.007 |